Prevalence of HCV-HIV coinfection. newborn babies

Similar documents
ANONYMOUS UNLINKED STUDY OF THE PREVALENCE OF ANTI- HIV ANTIBODIES IN MOTHERS OF LIVE NEWBORNS FROM 6 AUTONOMOUS REGIONS

Viral Hepatitis Burden and Policy Directions in the European Region of WHO

Supervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles

Strategies to Address HCV

EDMA HIV-AIDS TEAM Fact Sheet November 2007

Planning and health programmes

The current status of PrEP in Europe. Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint

STRATEGIES FOR MATERNO- FETAL TRANSMISSION OF HIV, HIV AND HBV COINFECTIONS IN CONSTANTA - ROMANIA

ECDC and Spanish Ministry of Health workshop:

Harm reduction among drug users in Spain

HIV/AIDS in China. -A A Potential epidemic? Kong-Lai Zhang, MD Professor, Department of Epidemiology, Peking Union Medical College Beijing, CHINA

HIV, HBV and HCV testing policy experiences and lessons learned.

Civil Society Driven Response in Ukraine: A program making a difference and bringing results

Consumer Price Index (CPI). Base 2006 October Monthly change Change over last December

Improving Access to Test and Counselling Services for Injection Drug Users: Most Recent Experience from Portugal. Henrique Barros

Government of Canada Federal AIDS Initiative Milestones

ECDC s role in the fight against HIV/AIDS in Europe

HIV EPIDEMIC UPDATE: FACTS & FIGURES 2012

HIV/Hepatitis co-infection situation in Romania. Oana Săndulescu, MD, PhD

Update on HCV and other infections related to injection drug use. Ann Thomas, MD, MPH Acute and Communicable Disease Prevention

Update on HIV-HCV Epidemiology and Natural History

Project SUCCEED Overview. Project Scaling-Up Co-Infection Care to End Ethnic Disparities Brooklyn Hep C Task Force February 6, 2018

Challenges for viral hepatitis prevention in Latin American

Metro St. Louis HIV Epidemiological Profile

Screening programmes for Hepatitis B/C in Europe

Current Hepatitis B and C Screening Practices for Migrants and Barriers to Screening

Hispanics/Latinos and Hepatitis: An Overlooked Health Disparity. National Hispanic Hepatitis Awareness Day

Hepatitis C reinfection after sustained virological response in HIV/HCV co-infected patients

Hepatitis situation in the Republic of Macedonia

Program to control HIV/AIDS

HIV and Paediatrics in Central Europe

HBV/HCV COINFECTIONS IN PATIENTS WITH HIV. Dr Reena Harania MBBS, MRCP, MSc Infectious Disease

Viral Hepatitis. WHO Regional Office for Europe July 2013

Tetiana Kyrychenko MD. Poltava Regional HIV/AIDS Prevention and Control Center. 4TH CEE MEETING ON VIRAL HEPATITIS AND HIV October 2018, Prague

Key issues for HIV testing and

DTD 1. Hepatitis C and HIV. Douglas T. Dieterich, MD Associate Professor of Medicine NYU School of Medicine

28.8% of deaths were due to diseases of the circulatory system and 26.7% to tumours

Project SUCCEED Scaling up Co Infection Care & Eliminating Ethnic Disparities 13 th Annual Iris House Women As the Face of AIDS Summit May 7th, 2018

10/07/18. Dr. Otilia Mårdh, ECDC. No conflicts of interest.

UNGASS COUNTRY PROGRESS REPORT SINGAPORE

HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications

HIV in the United Kingdom: 2009 Report

The evolution of HIV/AIDS Epidemic in Romania 31 December 2013

ECDC update to the EU Commission Think Tank on HIV/AIDS

STRATEGIC PLAN FOR TACKLING HEPATITIS C IN THE SPANISH NATIONAL HEALTH SYSTEM

Professor Norbert Bräu

HIV epidemic around the Baltic Sea

As a result of this training, participants will be able to:

HIV/AIDS in East Asia

ELIMINATION OF VIRAL HEPATITIS IN ROMANIA LESSONS LEARNT AND THE WAY FORWARD

Just Out of Reach: Women Who Use Drugs, Stigma and Barriers to Care Erin Bortel and Lyla Hunt AIDS Institute Office of Drug User Health

Public Health Response to HCV in Oregon: Need for Screening and Treatment. Ann Thomas, MD, MPH Acute and Communicable Disease Prevention

HIV in Prison Situation in Frankfurt am Main

Liver stiffness predicts liver related events and mortality in HIV/HCV coinfected patients

Who is a migrant? 12/10/2018. HIV and migrants. Heterogeneous groups of persons with different migration drivers

Treatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain

Linkage of hepatitis and HIV surveillance systems to improve completeness of injection drug use risk data for co-infected Floridians

HIV in Russia. Cost-effectiveness of Treating Injection Drug Users with Antiretroviral Therapy

INTRAVENOUS INJECTING DRUG USE.

EAST LONDON INTEGRATED CARE

Numbers HCV and HIV Epidemiology in the US

HIV-HBV coinfection in HIV population horizontally infected in early childhood between

Treatment of chronic hepatitis C in HIV co-infected patients

Consumer Price Index (CPI). Base 2011 May Monthly change Change over last May Annual change May

Outline. AIDS & HIV in the Travis County. Global estimates for adults & children end HIV incidence worldwide

Note: Staff who work in case management programs should attend the AIDS Institute training, "Addressing Prevention in HIV Case Management.

The Geography of Viral Hepatitis C in Texas,

Trends in HIV Incidence and Prevalence in the United States

ELPA S VISION OF SCREENING

Prevention and control of hepatitis B and C in the European Region of WHO

Hepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious Disease & Laboratory Sciences

Influence of Baseline HCV Genotype upon Treatment Outcome of Acute HCV Infection in HIV Co-Infected Individuals

Workbook Method for estimating HIV prevalence in low level or concentrated epidemics

S P. Strategic Planning and Priority Setting. Barry Kistnasamy Nelson Mandela School of Medicine University of KwaZulu-Natal

Module 1: HIV epidemiology, transmission and prevention

GLOBAL HIV STATISTICS

Missouri St. Louis TGA 2016 HIV Epidemiological Profile

Hepatitis C. Core slides

HIV/AIDS Joint Action HA-REACT

HIV coinfection and HCC

STRATEGIC PLAN AGAINST VIRAL HEPATITIS IN SENEGAL ( ) POLICY BRIEF

Welcome to Your Reading Assignment

PrEP for HIV prevention. Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint

Acute hepatitis C The European Experience

Mortality from viral hepatitis in the Netherlands. S.W. Schalm & M.Toy. Dpts Gastroenterology Hepatology and Public Health Erasmus MC, Rotterdam, NL

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Scottish Infected Blood Support Scheme. Payments for People Infected With Hepatitis C or HIV or both from Infected Blood

Formative Research results

Scaling up priority HIV/AIDS interventions in the health sector

Hepatitis B and C Basics

HPSC SEXUALLY TRANSMITTED INFECTIONS IN IRELAND, 2011

The evolution of HIV/AIDS infection in Romania 31 December 2017

Hepatitis is an epidemic disease that can be caused by different viruses including hepatitis viruses A, B, C, D or E.

Uses and Misuses of Viral Hepatitis Testing. Origins of Liver Science

Hepatitis C Seroprevalence Among HIV-Infected Childbearing Women in New York State in 2006

WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017

Poland nationalupdate

As a result of this training, participants will be able to:

SIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item April Viral hepatitis. Report by the Secretariat

Transcription:

Prevalence of HCV-HIV coinfection among mothers of newborn babies Mercedes Díez Secretariat of the National Plan on AIDS National Center of Epidemilogy Madrid, 24 November 26

Overview Background HIV epidemic in Spain Transmission patterns Overlap with HCV Unlinked Anonymous Testing (UAT) Methodology Results 1998-25 HIV prevalence Prevalence of HCV-HIV co-infection Conclusions

AIDS cases per million population in selected countries, 1986-24, western Europe 2 Cases per million 15 Update 3 June 25 1 5 1986 1988 199 1992 1994 1996 1998 2 22 24 Year of diagnosis Portugal Spain Italy France United Kingdom Germany EuroHIV

New annual AIDS cases by transmission category, adjusted for reporting delay. National AIDS Register. Updated June 3th, 26 5 45 4 IDU Homosexual Heterosexual 35 3 25 2 15 1 782 5 59 25 1981 1982 1983 1984 1985 1986 1987 1988 1989 199 1991 1992 1993 1994 1995 1996 1997 1998 1999 2 21 22 23* 24* 25*

AIDS cases diagnosed in 25, by sex and transmission category. National AIDS Register. Updated June 3th, 26 Trans/hem,3% Hetero. 23,9% MTCT,2% Hetero. 53,9% MTCT 1,2% Homosex. 19,8% Otros/desc 5,1% Other 7,8% Men (n = 1134) IDU 5,7% Trans/Hem,3% IDU 36,8% Women (n = 345)

New HIV diagnosis by transmission category Data from 7 AARR (21-24) Casos 5 45 4 35 3 25 2 15 1 5 IDU Hetero MSM MTCT 21 22 23 24 Data: Canary Islands, Catalonia,Ceuta, Navarra, Basque Country, Extremadura and La Rioja

9 8 No. of AIDS cases due to mother-to-child transmission, adjusted by reporting delay National AIDS Register. Update at June 3th, 26 HAART Inhibidores de la proteasa 7 6 5 Cases 4 3 2 1 1 4 6 1984 1985 1986 1987 1988 1989 199 1991 1992 1993 1994 1995 1996 1997 1998 1999 2 21 22 23* 24* 25*

Natural History of HCV infection FREE OF DISEASE PRIMOINFECTION 2-5% CLEARANCE 5-8% CRONIC HEPATITIS CIRRHOSIS 2% ACUTE HEPATITIS 8% Asyntomatic HEPATOCELULAR CARCINOMA 1,5% TIME

Hospital Discharge Diagnosis among deceased HIV/AIDS patients, 1999-22 1 9 Porcentaje sobre el total de fallecidos en cada año 8 7 6 5 4 3 2 1 26,8 3,4 34,8 4,7 7,5 4,7 68,5 62,1 6,5 41,9 5,8 52,3 1999 2 21 22 HIV-related AIDS indicative Disease Other χ2 test for trend: p<.5 Source: CMBD (1999-22)

Hospitalisations (N, %) due to viral hepatitis among HIV/AIDS patients, 1999-22 1999 2 21 22 N(%) N(%) N(%) N(%) Hepatitis C* 3.733 (17,6) 4.321 (21,) 4.916 (24,6) 5.211 (26,3) Hepatitis B 771 (3,6) 83 (4,) Other viral hepatitis 814 (4,1) 79 (4,) Hepatitis A 12 (,1) 12 (,1) 4 () 16 (,1) Hepatitis Delta (wth hep B) 14 (,1) 15 (,1) 2 (,1) 16 (,1) Hepatitis E 5 () 4 () 3 () 1 () Other 17 (,1) 14 (,1) 17 (,1) 6 (,1) A patient can have more than one diagnosis *p<.5 en χ2 test for trnd Source: CMBD

Hospitalisations (%) due to acute/chronic Hepatitis B or C among HIV/AIDS patients. 1999-22 3 25 p<.5 Porcentaje 2 15 1 p<.5 5 Acute Hep B Chronic Hep B Acute Hep C Chronic Hep C Hepatitis víricas A patient can have more than one diagnosis 1999 2 21 22 p: χ2 test for trnd Source: CMBD

To sum up... High HIV/AIDS incidence in Spain. Many years, highest in Western Europe Mature concentrated epidemic Intravenous drug users (IDU), most commonly represented transmission category, but epidemic pattern has changed recently IDUs also at high risk for HCV Need to prevent HIV and HCV MTCT Need to establish information systems to know HIV & HIV-HCV prevalence in general population

HIV Prev:,3% (3-7% co-infected with HCV) VIH HCV Prev HIV-HCV:?? VIH/VHC HCV Prev: 1,5-2,5% Distribution of HIV & HCV infection in the Spanish population Wordwide Prev HCV: 3% Source: WHO

Unlinked Anonimous Testing in newborn babies Epidemiological information system Iinitiated in 1998 Setting: 8 Autonomous Regions Residual dried blood spots samples from routine neonatal screening Unlinked for identifiers Tested anonymously for HIV. All HIVpositive samples tested for Anti- HVC

Methodology- Dried blood samples Type 1 Type 2

Objetives To estimate prevalence of HIV infection in mothers of newborn babies To estimate prevalence of HIV-HCV coinfection in mothers of newborn babies

UAT Results, 24 (7 AR) Blood Samples HIV(+) Anti-HCV in HIV(+) Autonomous Regions No. Tested HIV(+)/1 women (IC95%) Anti- HCV (n) Anti-HCV (%) (IC95%) Proportion HIV-HVC+ /HIV+ CANARY ISLANDS 9.39 2,15 (1,31-3,32) 4,43(,12-1,1) 2, CASTILLE- LEON 19.75 1,11 (,7-1,69) 8,41(,17-,8) 36,36 CASTILLE-LA MANCHA 6.981,86 (,32-1,87) GALICE MELILLA MURCIA C. VALENCIANA TOTAL 17.658 1.356 16.191 18.747 119.992 1,7 (1,15-2,42 ),74 (,2-4,1 ),8 (,43-1,37 ) 1,81 (1,45-2,22 ) 1,5 (1,29-1,74) 11 4 18 45,62 (,31-1,11),25 (,7-,63),37(,22-,58),38 (,27-,5) 37,93 36,36 21,69 26,47

Results. Period 1998-24 (5 AR) HIV HCV-HIV Autonomous Regions Number Tested Prev.HIV +/1 (IC95%) HCV + (n) Prev.HIV-HVC +/1 (IC95%) Proportion HIV-HVC+ /HIV+ CANARY ISLANDS 12,743 1.59 (1.35-1.85) 49.48 (.35-.63) 31.61 CASTILLE- LEON 16,662 1.3 (1.1-1.54) 5.47 (.35-.62 ) 42.74 GALICE 125,984 1.56 (1.35-1.8) 88.7 (.56-.86) 45.83 MELILLA 7,468.94 (.38-1.93) 1.13 (.-.75) 14.29 MURCIA 11,635 1.1 (.91-1.93) 34.33 (.23-.47) 37.36 TOTAL 444,492 1.39 (1.28-1.5) 222.5 (.44-.57) 39.5 HIV + (1998-24): 618 HCV tested HVC: 562 (9,9%)

HIV(+) mothers. Proportion with Anti-HCV 1998-24, 5 AARR 6 5 4 Percentage 3 2 1 39,5 1998 1999 2 21 22 23 24 98-24 Year HIV + (1998-24): 618 HCV tested HVC: 562 (9,9%)

HIV(+) mothers. Proportion with Anti-HCV by Autonomous Regions. 19988-24 Percentage 5 45 4 35 3 25 2 15 1 5 Canary Islands Castille-Leon Galice Murcia Melilla HIV + (1998-24): 618 Tested HVC: 562 (9,9%)

Prevalence of de HIV and HIV-HCV co-infection per 1 women (5 AARR) 2 Prevalence/1 women 1,6 1,2,8,4 1998 1999 2 21 22 23 24 98-24 Year HIV/1. HIV-HCV/1. Chi- Square of tendency: NS

Prevalence of HIV and HIV-HCV co-infection per 1 women. Canary Islands 6 p<.5 2,5 Percentage 5 4 3 2 1 2 1,5 1,5 Prevalence/1 women 1998 1999 2 21 22 23 24 98-24 % COINFECTION HIV/1. HIV-HCV/1. Chi- Square of tendency prevalence HIV/HCV: NS

Prevalence of HIV and HIV-HCV co-infection per 1 women. Castille-Leon 6 3 5 2,5 Percentage 4 3 2 1 2 1,5 1,5 Prevalence/1 women 1998 1999 2 21 22 23 24 98-24 % COINFECTION HIV/1. HIV-HCV/1. Chi- Square of tendency prevalence HIV/HCV and prevalence HIV: NS

Prevalence of HIV and HIV-HCV co-infection per 1 women. Galice 7 2,5 Percentage 6 5 4 3 2 1 2 1,5 1,5 Prevalence/1 women 1998 1999 2 21 22 23 24 98-24 % COINFECTION HIV/1. HIV-HCV/1. Chi- Square of tendency prevalence HIV/HCV and prevalence HIV: NS

Prevalence of HIV and HIV-HCV co-infection per 1 women. Murcia 6 1,8 Percentage 5 4 3 2 1 1,6 1,4 1,2 1,8,6,4,2 Prevalence/1 women 1998 1999 2 21 22 23 24 98-24 % COINFECTION HIV/1. HIV-HCV/1. Chi- Square of tendency prevalence HIV/HCV and prevalence HIV: NS

Conclusions UAT using residual dried blood spots samples from routine neonatal screening is feasible and costeffective It provides important information on HIV infection and HCV-HIV co-infection trends, in unselected group of the Spanish population Prevalence of HIV-ACV is high in comparison with other European countries, and stable during 1998-24 HCV testing should always be done in HIV(+) pregnant women, as well as in all those with risk factors for HCV infection Challenges: a) extend the program to other AARR; b) add some important epidemiological variables